RT Journal Article
SR Electronic
T1 MENSA, a Media Enriched with Newly Synthesized Antibodies, to Identify SARS-CoV-2 Persistence and Latent Viral Reactivation in Long-COVID
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.05.24310017
DO 10.1101/2024.07.05.24310017
A1 Haddad, Natalie S.
A1 Morrison-Porter, Andrea
A1 Quehl, Hannah
A1 Capric, Violeta
A1 Lamothe, Pedro A.
A1 Anam, Fabliha
A1 Runnstrom, Martin C.
A1 Truong, Alex D.
A1 Dixit, Adviteeya N.
A1 Woodruff, Matthew C.
A1 Chen, Anting
A1 Park, Jiwon
A1 Nguyen, Doan C.
A1 Hentenaar, Ian
A1 Kim, Caroline Y.
A1 Kyu, Shuya
A1 Stewart, Brandon
A1 Wagman, Elizabeth
A1 Geoffroy, Hannah
A1 Sanz, Daniel
A1 Cashman, Kevin S.
A1 Ramonell, Richard P.
A1 Cabrera-Mora, Monica
A1 Alter, David N.
A1 Roback, John D.
A1 Horwath, Michael C.
A1 O’Keefe, James B.
A1 Dretler, Alexandra W.
A1 Gripaldo, Ria
A1 Yeligar, Samantha M.
A1 Natoli, Ted
A1 Betin, Viktoria
A1 Patel, Rahulkumar
A1 Vela, Kennedy
A1 Hernandez, Mindy Rodriguez
A1 Usman, Sabeena
A1 Varghese, John
A1 Jalal, Anum
A1 Lee, Saeyun
A1 Le, Sang N.
A1 Toby Amoss, R.
A1 Daiss, John L.
A1 Sanz, Ignacio
A1 Lee, F. Eun-Hyung
YR 2024
UL http://medrxiv.org/content/early/2024/07/07/2024.07.05.24310017.abstract
AB Post-acute sequelae of SARS-CoV-2 (SARS2) infection (PASC) is a heterogeneous condition, but the main viral drivers are unknown. Here, we use MENSA, Media Enriched with Newly Synthesized Antibodies, secreted exclusively from circulating human plasmablasts, to provide an immune snapshot that defines the underlying viral triggers. We provide proof-of-concept testing that the MENSA technology can capture the new host immune response to accurately diagnose acute primary and breakthrough infections when known SARS2 virus or proteins are present. It is also positive after vaccination when spike proteins elicit an acute immune response. Applying the same principles for long-COVID patients, MENSA is positive for SARS2 in 40% of PASC vs none of the COVID recovered (CR) patients without any sequelae demonstrating ongoing SARS2 viral inflammation only in PASC. Additionally, in PASC patients, MENSAs are also positive for Epstein-Barr Virus (EBV) in 37%, Human Cytomegalovirus (CMV) in 23%, and herpes simplex virus 2 (HSV2) in 15% compared to 17%, 4%, and 4% in CR controls respectively. Combined, a total of 60% of PASC patients have a positive MENSA for SARS2, EBV, CMV, and/or HSV2. MENSA offers a unique antibody snapshot to reveal the underlying viral drivers in long-COVID thus demonstrating the persistence of SARS2 and reactivation of viral herpes in 60% of PASC patients.Graphical abstract Competing Interest StatementFEL is the founder of MicroB-plex, Inc. and serves on the scientific board of Be Biopharma, is a recipient of grants from the BMGF and Genentech, Inc., and has served as a consultant for Astra Zeneca. NSH and AMP were scientists at MicroB-plex, Inc., Atlanta, GA and JLD is a scientist at MicroB-plex, Inc., Atlanta, GA. IS has consulted for GSK, Pfizer, Kayverna, Johnson & Johnson, Celgene, Bristol Myer Squibb, and Visterra. FEL, DN, and IS are inventors of the patents concerning the plasma cell survival media related to this work (issued 9/21/21, US 11,124766 B2 PCT/US2016/036650; and issued 9/21/21, US 11,125757 B2). FEL & JLD are inventors of MENSA patent U.S. Patent No. 10,247,729. April 2, 2019. FEL, NSH, JLD, & IS are inventors of the MENSA PASC diagnostic provisional patent, March 28, 2024. All other authors have declared that no conflict of interest exists.Funding StatementThis work was supported by National Institute of Allergy and Infectious Diseases, National Institutes of Health 3P01AI125180-05S1, R01AI121252, R01AI 172254, P01A1078907, U01AI045969, U19AI109962, U54CA260563, T32HL116271-07, and NIGMS 2T32GM095442, NIH Department of Health and Human Services/Public Health Services: 5T32AI74492-14.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Emory University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study will be available upon reasonable request to the authors.